STK11 and non-small cell lung carcinoma: Investigating if the metabolic changes resulting from LKB1 loss may also affect TME cell function, including CAFs, could broaden our knowledge about the LKB1less phenotype, thus potentially suggesting new therapeutic strategies for LKB1-inactive NSCLC treatment.